Aclaris Therapeutics (ACRS) FCF Margin (2017 - 2025)
Historic FCF Margin for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 332.07%.
- Aclaris Therapeutics' FCF Margin fell 8382800.0% to 332.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 273.2%, marking a year-over-year decrease of 2050300.0%. This contributed to the annual value of 107.88% for FY2024, which is 1469500.0% up from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' FCF Margin is 332.07%, which was down 8382800.0% from 563.53% recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' FCF Margin registered a high of 506.21% during Q3 2024, and its lowest value of 1454.44% during Q1 2022.
- In the last 5 years, Aclaris Therapeutics' FCF Margin had a median value of 642.68% in 2021 and averaged 599.42%.
- Its FCF Margin has fluctuated over the past 5 years, first surged by 9030000bps in 2022, then crashed by -8382800bps in 2025.
- Quarter analysis of 5 years shows Aclaris Therapeutics' FCF Margin stood at 1150.9% in 2021, then skyrocketed by 78bps to 247.9% in 2022, then skyrocketed by 83bps to 40.99% in 2023, then crashed by -137bps to 97.04% in 2024, then crashed by -242bps to 332.07% in 2025.
- Its FCF Margin stands at 332.07% for Q3 2025, versus 563.53% for Q2 2025 and 900.34% for Q1 2025.